Jiangsu Nanfang Medical Co., Ltd. (603880.SS)
- Previous Close
5.34 - Open
5.36 - Bid 5.37 x --
- Ask 5.38 x --
- Day's Range
5.30 - 5.48 - 52 Week Range
3.08 - 5.99 - Volume
8,610,990 - Avg. Volume
5,804,486 - Market Cap (intraday)
1.552B - Beta (5Y Monthly) 0.54
- PE Ratio (TTM)
-- - EPS (TTM)
-0.70 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date May 21, 2021
- 1y Target Est
--
Jiangsu Nanfang Medical Co., Ltd. engages in the research and development, production, and sale of transdermal products, medical adhesive tapes and bandages, first aid kits, sports protection products, protective products, and nursing products in China and internationally. The company offers transdermal products, such as plasters, dressings, and bandages; and protective equipment comprising daily protective masks, disposable medical masks, medical surgical masks, medical nitrile examination gloves, and medical examination gloves. It offers medical wound dressings, capsicum plasters, physical therapy tapes, pain relief sleeves, rigid sports tapes, wound plaster dressings, medical eye pads, elastic stretch tapes, corn removal plasters, waterproof adhesive tapes, pain relief patches, kinesiology tapes, surgical tapes, zinc oxide adhesive plasters, and masks, as well as customized products. Jiangsu Nanfang Medical Co., Ltd. was founded in 1990 and is based in Changzhou, China.
www.nfmedical.com.cnRecent News: 603880.SS
View MorePerformance Overview: 603880.SS
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 603880.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 603880.SS
View MoreValuation Measures
Market Cap
1.55B
Enterprise Value
1.98B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.45
Price/Book (mrq)
5.72
Enterprise Value/Revenue
3.12
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-28.72%
Return on Assets (ttm)
-5.00%
Return on Equity (ttm)
-30.73%
Revenue (ttm)
584.85M
Net Income Avi to Common (ttm)
-167.99M
Diluted EPS (ttm)
-0.70
Balance Sheet and Cash Flow
Total Cash (mrq)
90.13M
Total Debt/Equity (mrq)
112.52%
Levered Free Cash Flow (ttm)
-46.32M